文献速递免疫规划

在日本、韩国和台湾地区60岁及以上成人中接种20价肺炎球菌结合疫苗安全性和免疫原性的3期随机试验

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
PubMed 文献 · Vaccine · 2024-01-23

这项3期随机双盲研究在日本、韩国和台湾地区≥60岁成人中比较PCV20与PCV13的安全性及免疫原性,共1421人接种。接种后1个月,PCV20对13个匹配血清型的调理吞噬活性几何平均滴度非劣效于PCV13,对7个额外血清型中的6个非劣效于PPSV23;血清型8未达非劣效标准但次要终点支持稳健免疫应答,安全性总体与PCV13相似。

要点

  • PCV20对13个匹配血清型的OPA GMT非劣效于PCV13。
  • PCV20对7个额外血清型中6个非劣效于PPSV23。
  • 血清型8未达非劣效标准,但次要免疫原性终点支持稳健应答。

核心结论

  • PCV20在日本、韩国和台湾地区老年成人中对所有疫苗血清型产生稳健免疫应答,安全性和耐受性与PCV13相似,预期有助于预防全部20个疫苗血清型。

研究设计与样本

  • 3期随机双盲研究,纳入日本、韩国和台湾地区≥60岁参与者,随机接种PCV20或PCV13,共1421人接种,中位年龄65岁(范围60-85岁)。
  • 接种1个月后,PCV20组接受生理盐水注射,PCV13组接受23价多糖疫苗(PPSV23)。

主要发现

  • PCV20对全部13个匹配血清型的OPA GMT非劣效于PCV13。
  • PCV20对7个额外血清型中的6个非劣效于PPSV23。
  • 血清型8的OPA GMR双侧95%CI下限=0.5,未满足>0.5的非劣效标准,但血清型8的次要免疫原性终点支持稳健免疫应答。
  • PCV20与PCV13接种后不良事件发生率及局部反应和全身事件频率与严重程度总体相似,未发现安全性问题。

关键数值与推荐

  • 每个血清型OPA GMR双侧95%CI下限>0.5时判定非劣效。
  • 主要免疫原性目标为接种PCV20、PCV13或PPSV23后1个月血清型特异性OPA GMT的非劣效性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal infections are associated with high disease burden in older individuals in Japan, South Korea, and Taiwan. The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to extend protection beyond earlier pneumococcal vaccines. METHODS: This phase 3 randomized, double-blind study investigated the safety and immunogenicity of PCV20 in participants ≥ 60 years of age from Japan, South Korea, and Taiwan. Participants were randomized to receive PCV20 or 13-valent pneumococcal conjugate vaccine (PCV13). One month after vaccination, PCV20 recipients received a saline injection and PCV13 recipients received 23-valent polysaccharide vaccine (PPSV23). Primary immunogenicity objectives were to demonstrate noninferiority of PCV20 to PCV13 (13 matched serotypes) or PPSV23 (7 additional serotypes) for serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) 1 month after vaccination with PCV20, PCV13, or PPSV23. Noninferiority for each serotype was declared if the lower bound of the 2-sided 95% CI for OPA geometric mean ratio (GMR) was > 0.5. Safety endpoints included local reactions, systemic events, adverse events (AEs), and serious AEs. RESULTS: Overall, 1421 participants were vaccinated (median age [range]: 65 [60-85] years). PCV20 was noninferior to PCV13 for all 13 matched serotypes and to PPSV23 for 6 of 7 additional serotypes. Although statistical noninferiority was missed for serotype 8 (lower bound of the 2-sided 95% CI for OPA GMR = 0.5, thus not meeting the statistical noninferiority criterion of > 0.5), secondary immunogenicity endpoints for serotype 8 were supportive of a robust immune response. The incidence of AEs and the frequency and severity of local reactions and systemic events were generally similar after PCV20 and PCV13. No safety concerns were identified. CONCLUSION: PCV20 generated robust immune responses to all vaccine serotypes in older adults in Japan, South Korea, and Taiwan. The safety and tolerability profile was similar to PCV13. PCV20 is expected to help protect against all 20 vaccine serotypes. NCT04875533.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Haranaka M, Young Song J, Huang KC, et al. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan. Vaccine. 2024. PMID: 38267330. doi:10.1016/j.vaccine.2024.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。